MGX

+ Watchlist + Portfolio

Metagenomi Therapeutics, Inc.

Regulated industry Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $1.11
52-Week Range: $1.02 – $3.95
Market Cap: $38.53M
P/E (TTM): —
EPS (TTM): -2.49
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 0.34
PEG Ratio: —
Return on Equity: -60.61%
Return on Assets: -28.19%
Gross Margin: 0.00%
Operating Margin: 11195.72%
Profit Margin: 0.00%
Current Ratio: 4.50
Debt/Equity: 0.34
Total Debt: $37.72M
Free Cash Flow: $-50.95M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $-44.41M

MGX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$17.20M	$44.76M	$52.30M	$25.21M
Research & Development	$43.14M	$94.40M	$109.18M	$94.43M
Selling, General & Admin	$18.70M	$28.84M	$32.02M	$26.79M
Operating Expenses	$61.84M	$123.25M	$141.20M	$121.22M
Operating Income	-$44.64M	-$78.49M	-$88.90M	-$96.01M
EBITDA	-$39.19M	-$74.28M	-$83.49M	-$90.70M
Pretax Income	-$41.02M	-$60.23M	-$83.57M	-$87.93M
Income Tax	$2.57M	$8.03M	-$5.51M	-$58.00K
Net Income	-$43.59M	-$68.25M	-$78.06M	-$87.87M
Diluted EPS	-1.45	-1.82	-2.36	-2.36
Diluted Shares	29.96M	37.53M	33.03M	37.25M

MGX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$184.44M	$140.60M	$27.39M	$41.72M
Receivables	$1.27M	$2.45M	$1.26M	$305.00K
Current Assets	$366.90M	$278.27M	$257.96M	$165.54M
Total Assets	$414.49M	$364.84M	$324.60M	$221.10M
Current Liabilities	$48.54M	$68.86M	$37.31M	$22.93M
Total Debt	$18.57M	$48.23M	$45.78M	$40.66M
Total Liabilities	$488.91M	$500.43M	$89.74M	$62.51M
Retained Earnings	-$76.69M	-$144.94M	-$223.00M	-$310.87M
Shareholders' Equity	-$74.43M	-$135.58M	$234.86M	$158.60M
Working Capital	$318.36M	$209.41M	$220.65M	$142.60M

MGX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$29.72M	-$91.41M	-$109.07M	-$88.89M
Capital Expenditure	-$13.98M	-$9.81M	-$3.11M	-$574.00K
Free Cash Flow	$15.75M	-$101.22M	-$112.19M	-$89.47M
Depreciation & Amortisation	$1.73M	$4.21M	$5.41M	$5.32M
Stock-Based Compensation	$1.96M	$6.92M	$16.20M	$11.85M
Investing Cash Flow	-$122.20M	$45.73M	-$88.16M	$103.53M
Financing Cash Flow	$239.59M	$1.01M	$84.01M	-$356.00K
Net Change in Cash	$147.12M	-$44.66M	-$113.22M	$14.28M

MGX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$4.13M	$8.51M	$8.66M	$3.91M	$1.25M	-$257.00K
Research & Development	$25.14M	$22.51M	$25.28M	$21.50M	$19.30M	$22.51M
Selling, General & Admin	$6.80M	$6.99M	$6.21M	$6.78M	$6.54M	$6.00M
Operating Expenses	$31.95M	$29.50M	$31.50M	$28.28M	$25.84M	$28.52M
Operating Income	-$27.82M	-$20.99M	-$22.84M	-$24.37M	-$24.59M	-$28.77M
EBITDA	-$26.46M	-$19.65M	-$21.52M	-$23.07M	-$23.31M	-$27.51M
Pretax Income	-$24.94M	-$19.86M	-$20.63M	-$22.49M	-$23.05M	-$27.48M
Income Tax	$98.00K	$44.00K	-$234.00K	$34.00K	$10.00K	$0.00
Net Income	-$25.04M	-$19.91M	-$20.39M	-$22.53M	-$23.06M	-$27.48M
Diluted EPS	-0.68	-0.54	-0.55	—	-0.61	-0.73
Diluted Shares	37.02M	37.16M	37.35M	—	37.58M	37.66M

MGX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$29.20M	$26.85M	$32.77M	$41.72M	$25.31M	$39.03M
Receivables	$1.01M	$873.00K	$960.00K	$305.00K	$0.00	$0.00
Current Assets	$233.19M	$211.68M	$189.82M	$165.54M	$144.56M	$124.47M
Total Assets	$297.87M	$272.28M	$247.94M	$221.10M	$196.95M	$173.70M
Current Liabilities	$39.89M	$33.27M	$29.58M	$22.93M	$22.50M	$27.63M
Total Debt	$44.44M	$42.99M	$41.66M	$40.66M	$39.19M	$37.72M
Total Liabilities	$85.21M	$76.45M	$69.49M	$62.51M	$59.17M	$61.13M
Retained Earnings	-$248.04M	-$267.95M	-$288.34M	-$310.87M	-$333.93M	-$361.41M
Shareholders' Equity	$212.66M	$195.83M	$178.45M	$158.60M	$137.78M	$112.57M
Working Capital	$193.30M	$178.42M	$160.24M	$142.60M	$122.06M	$96.84M

MGX Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$22.84M	-$21.25M	-$21.25M	-$23.55M	-$21.18M	-$19.51M
Capital Expenditure	-$288.00K	-$127.00K	-$74.00K	-$85.00K	-$25.00K	-$125.00K
Free Cash Flow	-$23.13M	-$21.38M	-$21.33M	-$23.63M	-$21.20M	-$19.64M
Depreciation & Amortisation	$1.36M	$1.33M	$1.32M	$1.30M	$1.27M	$1.26M
Stock-Based Compensation	$2.93M	$3.22M	$3.01M	$2.69M	$2.55M	$2.27M
Investing Cash Flow	$24.73M	$19.07M	$27.36M	$32.37M	$3.99M	$33.17M
Financing Cash Flow	-$77.00K	-$166.00K	-$187.00K	$74.00K	-$27.00K	$67.00K
Net Change in Cash	$1.81M	-$2.35M	$5.92M	$8.89M	-$17.22M	$13.72M

Market Snapshot

About

Metagenomi Therapeutics is a genetic medicines company developing gene editing and gene writing therapies. The company uses its proprietary metagenomics platform to discover novel genome editing systems for treating genetic diseases.